SFM
ADMA icon

Sphera Funds Management’s ADMA Biologics ADMA Stock Holding History

Sphera Funds Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,081,292
Closed -$2.58M – 111
2020
Q3 		$2.58M Sell
1,081,292
-903,657
-46% -$2.48M 0.25% 76
2020
Q2 		$5.82M Buy
1,984,949
+146,849
+8% +$422K 0.55% 47
2020
Q1 		$5.29M Buy
1,838,100
+1,298,100
+240% +$4.49M 0.66% 31
2019
Q4 		$2.16M Buy
+540,000
New +$2.35M 0.18% 75

Other funds holding ADMA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Sphera Funds Management's ADMA Position: Q4 2020 in Review

Sphera Funds Management sold out of ADMA Biologics (ADMA) in Q4 2020, closing a stake of 1,081,292 shares — an estimated $2.58M sold.

Sphera Funds Management first reported a position in ADMA in Q4 2019 and held it in 4 quarters. The position peaked at $5.82M in Q2 2020. 94 funds tracked by Wall St. Rank hold ADMA as of Q4 2020.

  • Sphera Funds Management reported no remaining ADMA Biologics position as of Q4 2020 after selling out during the quarter.
  • Sphera Funds Management sold 1,081,292 ADMA Biologics shares in Q4 2020, an estimated $2.58M.
  • Sphera Funds Management first reported a position in ADMA Biologics in Q4 2019 and held it in 4 quarters.
  • Sphera Funds Management's ADMA Biologics position peaked at $5.82M in Q2 2020.
  • 94 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2020.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.